A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Cetuximab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 31 Aug 2017.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology